ESR1 and breast cancer: Consistent with the resistance of TC11 tumors to estrogen receptor antagonists [26] (and data herein), fulvestrant did not increase the intrinsic radiosensitivity of TC11 tumor cells in vitro, in contrast to other breast cancer cell lines that are dependent on estrogen for growth [32].